2006
DOI: 10.1007/s00066-006-1454-7
|View full text |Cite
|
Sign up to set email alerts
|

Neoadjuvante interstitielle HDR-Brachytherapie in Kombination mit Chemotherapie bei Patientinnen mit Mammakarzinom

Abstract: The combination of interstitial HDR brachytherapy and chemotherapy is a well-tolerated and effective neoadjuvant treatment in patients with breast cancer. Compared to EBRT, treatment time is short. Postoperative EBRT of the whole breast -- if necessary -- is still possible after neoadjuvant brachytherapy. Even though the number of patients does not permit definite conclusions, the results are promising regarding survival and the very low rate of local recurrences.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
9
0

Year Published

2007
2007
2016
2016

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 42 publications
0
9
0
Order By: Relevance
“…Although this technique requires more preparation time and planning than standard ones [3,7,11], these efforts seem to be justified regarding the achievable results and the small number of cases occurred. The planning can be effected using the systems available and, as shown in our description, it can be verified relatively easily and with great accuracy (e.g., by TLD).…”
Section: Discussionmentioning
confidence: 99%
“…Although this technique requires more preparation time and planning than standard ones [3,7,11], these efforts seem to be justified regarding the achievable results and the small number of cases occurred. The planning can be effected using the systems available and, as shown in our description, it can be verified relatively easily and with great accuracy (e.g., by TLD).…”
Section: Discussionmentioning
confidence: 99%
“…Accelerated partial-breast irradiation (APBI) with interstitial pulsed-dose-rate (PDR) or high-dose-rate (HDR) brachytherapy regimens recently became a field of much interest in radiooncologic research [12,14,21,22]. Data from quality-assured phase II trials increasingly underlined the safety and efficacy of this treatment approach for a highly selected subgroup of breast cancer patients with a genuine low risk of local recurrence [2,3,9,16,17,20,23].…”
Section: Introductionmentioning
confidence: 99%
“…Novel approaches, including radiotherapy, are needed to increase the pCR rate for LABC. Combined neoadjuvant chemoradiotherapy has been studied including neoadjuvant highdose rate brachytherapy (BRT) (13,14), but these modalities are difficult to organize and deliver effectively in the neoadjuvant setting and notably in some cases have resulted in acute radiation-induced side effects (15).…”
mentioning
confidence: 99%